A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities ...

A booming gray market is turning kitchens into makeshift pharmacies as Americans chase cheaper alternatives to high-priced ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Amy Spencer, a Missouri-based pioneer, navigates the unregulated gray market of obesity medicines. Utilizing drugs like Eli Lilly's Zepbound under the radar, Spencer reduces her weight and costs ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

As Ohio cuts off state employees' coverage of medications for weight loss, a lawmaker who has benefited from the drugs wants to bring them back.

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.